Rituximab Resistance in Glomerular Diseases: A GlomCon Mini Review

• DOI: 10.1016/j.xkme.2024.100791
• Publication Date: 2024-02-16T17:59:03Z
• Authors: Tania Salehi; Anoushka Krishnan; Ayman Al Jurdi; Paolo So; Edgar Lerma; Nasim Wiegley
• Keywords: 0301 basic medicine; glomerular disease; Diseases of the genitourinary system. Urology; human antichimeric antibodies; 0302 clinical medicine; rituximab resistance; Nephrology; Antidrug antibodies; GlomCon Mini Review; RC870-923; B-cell depletion therapy; CD20 antigen

Resistance to rituximab B-cell depletion therapy is a clinically pertinent adverse sequela that can have significant implications for the treatment of immune-mediated glomerular diseases. The true incidence resistance remains unknown; however, it an increasingly recognized complication. typically presents with suboptimal response, rapid reconstitution, and relapsing disease course. Although diverse mechanisms resulting in are ongoing topics research, both primary secondary been identified as key catalysts. emergence human antichimeric antibodies (HACAs) major cause appears following repeated drug exposure. Frequently, HACAs develop setting underlying autoimmune contribute poor depletion, reduced therapeutic efficacy, enhanced clearance. clinical challenge necessitates heightened awareness among clinicians. Screening should be considered individuals response rituximab, more disease. Detection may guide alterations, including addition further immunosuppressive transitioning humanized depleting monoclonal antibody.